Your browser doesn't support javascript.
loading
Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso.
Kadanga, Essonan; Zouré, Abdou Azaque; Zohoncon, Théodora M; Traoré, Lassina; Ky, Bienvenu Désiré; Yonli, Albert Théophane; Traoré, Djé Djénèba Aïda; Bazié, Bapio Valery Jean Télesphore Elvira; Sombié, Herman Karim; Sorgho, Pegdwendé Abel; Tovo, Sessi Frida Appoline; Traoré, Kalifou; Ouedraogo, Teega-Wendé Clarisse; Djigma, Florencia W; Simpore, Jacques.
Affiliation
  • Kadanga E; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Zouré AA; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Zohoncon TM; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso. abdouazaque@gmail.com.
  • Traoré L; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso. abdouazaque@gmail.com.
  • Ky BD; Biomedical Research Laboratory (LaReBio), Biomedical and Public Health Department, Institute for Research in Health Sciences (IRSS/CNRST), 03 BP 7192, Ouaga 03, Burkina Faso. abdouazaque@gmail.com.
  • Yonli AT; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Traoré DDA; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Bazié BVJTE; Faculty of Medicine, Saint Thomas Aquinas University (USTA), 06 BP 10212, Ouagadougou 06, Burkina Faso.
  • Sombié HK; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Sorgho PA; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Tovo SFA; Urology Department, CHU Yalgado Ouedraogo, UFR SDS, Joseph KI ZERBO University, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso.
  • Traoré K; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Ouedraogo TC; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Djigma FW; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Simpore J; Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
BMC Med Genomics ; 15(1): 123, 2022 06 02.
Article in En | MEDLINE | ID: mdl-35655265
BACKGROUND: Prostate cancer (Pca) is a public health problem that affects men, usually of middle age or older. It is the second most common cancer diagnosed in men and the fifth leading cause of death. The RNASEL gene located in 1q25 and identified as a susceptibility gene to hereditary prostate cancer, has never been studied in relation to prostate cancer in Burkina Faso. The aim of this study was to analyze the carriage of RNASEL R462Q and D541E mutations and risks factors in patients with prostate cancer in the Burkina Faso. METHODS: This case-control study included of 38 histologically diagnosed prostate cancer cases and 53 controls (cases without prostate abnormalities). Real-time PCR genotyping of R462Q and D541E variants using the TaqMan® allelic discrimination technique was used. Correlations between different genotypes and combined genotypes were investigated. RESULTS: The R462Q variant was present in 5.3% of cases and 7.5% of controls. The D541E variant was present in 50.0% of cases and 35% of controls. There is no association between R462Q variants (OR = 0.60; 95%IC, 0.10-3.51; p = 0.686) and D541E variants (OR = 2.46; 95%IC, 0.78-7.80; p = 0.121) and genotypes combined with prostate cancer. However, there is a statistically significant difference in the distribution of cases according to the PSA rate at diagnosis (p ˂ 0.001). For the Gleason score distribution, only 13.2% of cases have a Gleason score greater than 7. There is a statistically significant difference in the Gleason score distribution of cases (p ˂ 0.001). CONCLUSIONS: These variants, considered in isolation or in combination, are not associated with the risk of prostate cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Endoribonucleases Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: BMC Med Genomics Journal subject: GENETICA MEDICA Year: 2022 Document type: Article Affiliation country: Burkina Faso Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Endoribonucleases Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: BMC Med Genomics Journal subject: GENETICA MEDICA Year: 2022 Document type: Article Affiliation country: Burkina Faso Country of publication: United kingdom